Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT001 ± temozolomide vs temozolomide or lomustine in recurrent glioblastoma
ChiCTR2000035315Phase 2Completed
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Jun 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dimethylaminomicheliolide in glioblastoma (GBM) (3 arms), sponsored by Tianjin Medical University General Hospital. Primary endpoint: 1-year survival rate. Started Jun 2020; status: completed.
02
Drugs
dimethylaminomicheliolide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR2000035315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035315.